Research guide · Cellular Energy
SS-31 — research protocol
Mitochondria-targeting peptide studied for cellular energy and oxidative stress studies.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Mitochondria-targeted
- Oxidative stress
- Lyophilized stability
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
SS-31 (elamipretide) is a synthetic four-amino-acid peptide that stabilizes the inner mitochondrial membrane by binding cardiolipin. It is FDA-approved as FORZINITY for Barth syndrome patients weighing at least 30 kg to improve muscle strength, or available as research-use vials.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Forzinity (FDA Label) - Patients ≥30 kg | 40 mg | Once daily | Continuous | Subcutaneous |
| Forzinity (FDA Label) - Adults with severe renal impairment (eGFR <30 mL/min, not on dialysis) | 20 mg | Once daily | Continuous | Subcutaneous |
| TAZPOWER (Trial Context) - Elamipretide arm | 40 mg SC daily | Daily | 12 weeks per period, with 4-week washout | Subcutaneous |
| TAZPOWER (Trial Context) - Open-label extension | 40 mg SC daily | Daily | Up to 168 weeks | Subcutaneous |
Cycle: Forzinity label use is continuous, once daily, per prescriber. TAZPOWER trial arms included 12-week periods or up to 168 weeks in the open-label extension.
Benefits and research observations: Endpoints were measured at week 12 (no significant difference vs. placebo), week 36 (improvement from baseline), week 64-76 (improved 6MWT), and week 168 (improved 6MWT and knee extensor strength). Clinicians may monitor renal function, injection-site appearance, disease-specific endpoints, and hypersensitivity history.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Szeto HH. Br J Pharmacol, 2014.
- 2.Birk AV, et al. JASN, 2013.